COVID-19 Therapeutics 



At various times during the COVID-19 pandemic, Montana DPHHS has been involved in the distribution of therapeutics purchased by the federal government. This website is designed to provide brief background material on the state-allocated COVID-19 medications and provide information to assist in identifying administration or distribution site locations.

The National Institutes of Health (NIH) offers the Therapeutic Management of Nonhospitalized Adults with COVID-19, which provides recommendations for the preferred and alternative COVID-19 medications used as treatment for nonhospitalized patients with mild to moderate COVID-19 who are high risk of progressing to severe disease. Health and Human Services (HHS) has created the Side by Side Therapeutics Overview and the COVID-19 Therapeutics Decision Aid.

Oral Antivirals

Two oral COVID-19 antiviral medications are available for non-hospitalized patients at high risk for progression to severe COVID-19. These therapeutics will be transitioned from a state-based allocation of U.S. Government (USG)-purchased supply to private purchase from the commercial marketplace in the coming months. I have included important dates for your consideration below as we transition from a state-based allocation of USG-purchased products to commercial access. Please see the ASPR Guidance, Sunsetting the US Government COVID-19 Therapeutics Distribution Program


Paxlovid (nirmatrelvir and ritonavir) – minimum order quantity 20 courses for regular Paxlovid and 5 courses for renal Paxlovid 

    • This medication will be available for commercial purchase on November 1st.
    • Partners are encouraged to place requests in HPoP prior to 1 pm MST on November 27th because state thresholds will be set to zero at that time.
    • The USG-purchased supply will remain available by an out-of-cycle request in HPoP until 1 pm MST on December 15th. These requests will be processed as they are received.
    • After 1 pm MST on December 15th, the USG-purchased supply will no longer be available.


    Please review shelf-life extensions by your medication lot - Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and ritonavir).

    Montana has a fixed threshold of the USG-purchased supply until the transition to commercialization is complete, as above. These USG-purchased supplies remain free to the consumer.  Please order only what you need during this transition. Please contact with questions.

    For retail pharmacies that would like to learn more about participating in the U.S. Government Patient Assistance Program once commercialization is complete, please contact the program vendor at


Lagevrio (molnupiravir) - minimum order quantity 15 courses  

  • This medication will be available for commercial purchase on November 1st.
  • The USG-purchased supply will be available by request in HPoP until 1 pm MST on November 10th. These requests will be processed as they are received.
  • After 1 pm MST on November 10th, the USG-purchased supply will no longer be available.

COVID-19 Medication Sites in Montana  

To identify COVID-19 medication dispensing sites in Montana, please visit the links below and search for administration sites by zip code.

To find sites reporting inventory of Lagevrio (molnupiravir), Paxlovid, Renal Paxlovid, and outpatient commercial remdesivir visit the HHS Therapeutics Distribution Locator for Provider Use.

Patients must qualify for treatment. Product availability may change based on access to the monoclonal antibody products and demand. Potential recipients should contact the site before presenting for treatment.  Please note that this website discusses therapeutics distributed as a part of the state-led allocation and may not reflect all treatment sites in the state. Sites purchasing product commercially and those involved in a direct federal allocation are not included on this map, as that allocation occurs independent of the state (e.g., Veterans Affairs or Indian Health Service).